Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs British American Tobacco PLC (BTI) Price & Performance

Amgen, Inc.Trade
British American Tobacco PLCTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs British American Tobacco PLC — how do they compare? Amgen, Inc. trades at $415.37 (market cap $224.14B), while British American Tobacco PLC trades at $56.06 (market cap $122.36B). The key difference: Amgen, Inc. is the larger of the two by market cap, and British American Tobacco PLC pays the higher dividend (5.88%). Which is the better fit depends on your goals.

AMGNBTI
Market Cap
$224.14B$122.36B
Sector
HealthConsumer Staples
52-Week High
$417.20$66.70
52-Week Low
$271.18$50.39
Enterprise Value
$267.45B$166.31B
Dividend Yield
2.43%5.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

British American Tobacco PLC

BTI trades at $55.93, down 1.96% today, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with an 83.56% gross margin and 24.99% net income margin, supported by a P/E of 14.48. Recent news highlights strategic tech partnerships and workforce restructuring to drive efficiency.

The outlook is cautious due to declining cash flow and regulatory risks, but the 5%+ dividend yield and analyst buy consensus (66.7%) offer value. Upside depends on successful transition to next-generation products, while core combustible declines and debt levels pose challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About British American Tobacco PLC

Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.

Read more on BTI